A
Agomab
Developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues
About Agomab
Agomab Therapeutics NV, or simply Agomab, is a biopharmaceutical startup that specializes in the development of treatments for fibrotic diseases, with a particular focus on Fibrostenosing Crohn’s Disease (FSCD). Fibrotic diseases are conditions characterized by the thickening and scarring of connective tissue, often leading to organ damage and failure. Agomab's mission is to restore organ function and improve the lives of patients suffering from these conditions.
Read full description
The company operates in the biotech and healthcare market, serving a client base primarily composed of patients with fibrotic diseases. Agomab's business model revolves around the research, development, and commercialization of innovative therapeutics. Its primary revenue stream is expected to come from the sales of its drugs once they receive regulatory approval and are brought to market.
Agomab has recently raised $100 million in a Series C financing round, indicating strong investor confidence in its potential. The company has also received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, AGMB-129, a drug designed to treat FSCD. This designation will expedite the review of AGMB-129, potentially bringing it to market faster.
The company's recent initiation of the STENOVA Phase 2a clinical trial for AGMB-129, following positive Phase 1 results, further underscores its progress in developing effective treatments for fibrotic diseases.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Antwerp, Belgium
- Employees
- 72
- Open positions
- 5
- Dealroom signal
- 79.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Antibodies, Inflammatory Diseases, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2026 | $200M | $716M | Undisclosed | ↗ |
| SERIES DOther financing | Oct 2024 | $89M | $500M | Invus · Sanofi | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Agomab is 9.1K monthly website visits, up 15.2% over the last three months. Agomab's team grew 2.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
V-Bio Ventures
AdBio partners
Redmile Group
Omnes Capital
Pontifax Funds
Cormorant Asset Management
Andera Partners
Boehringer Ingelheim Venture Fund
Pfizer
Asabys Partners
Walleye Capital
Series B and later6 investors entered at this stage
Fidelity Investments
Canaan
EQT Life Sciences
Dawn Biopharma
Invus
Sanofi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Agomab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Agomab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.